A 24-year-old man is diagnosed with active ankylosing spondylitis characterized by progressive inflammatory back pain, elevated inflammatory markers, and severe morning stiffness. Arrange the following therapeutic interventions in the standard chronological sequence for escalating disease management, from initial first-line therapy to end-stage treatment.
- 1Prescribe an aggressive, continuous regimen of nonsteroidal anti-inflammatory drugs (NSAIDs).
- 2Initiate a biologic disease-modifying antirheumatic drug, such as a TNF-alpha inhibitor.
- 3Switch to an alternative biologic agent, such as an IL-17 inhibitor.
- 4Perform corrective spinal surgery or total joint arthroplasty.
Answer
The correct sequence for managing ankylosing spondylitis escalates from continuous NSAIDs, to a TNF-alpha inhibitor, then to an IL-17 inhibitor if the first biologic fails, and finally to surgery for end-stage structural damage.
The standard management pathway for ankylosing spondylitis (AS) strictly follows a step-up approach. Initial management relies on continuous NSAIDs, which effectively control symptoms and are the cornerstone of early therapy. When patients have refractory symptoms or objectively high disease activity despite an adequate NSAID trial, escalation to a biologic DMARD, typically a TNF-alpha inhibitor, is indicated. If primary non-response or secondary loss of response occurs with the first biologic, switching to a different class, such as an IL-17 inhibitor, is the next logical pharmacological step. Finally, surgical interventions (e.g., spinal osteotomy) are reserved as a last resort for severe complications of advanced structural disease.
Step-by-Step Solution
Key Concept
Step-up pharmacological and surgical management pathway for ankylosing spondylitis.
Estimated Time:1m 0s